Philly Biotech Co. Develops High-Potential Autoimmune Therapy Breakthrough
Source: Streetwise Reports  (4/2/26)
Cabaletta Bio Inc. (CABA:NASDAQ) pushes rese-cel CAR T program forward with strong clinical momentum, production scalability, and analyst-backed upside potential. More >

The World's First AI Voice Detection For Drugs & Alcohol With Charts That Beckon Investors To Buy
Source: Stewart Thomson  (4/1/26)
Technical Analyst Stewart Thomson explains why he thinks MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) is a Speculative Buy. More >

Biotech Company Uncovers Breakthrough Canine Arthritis Treatment
Source: Streetwise Reports  (3/30/26)
Israeli co. Can-Fite BioPharma Ltd. (CANF:NYSEAmerican) teamed up with Vetbiolix to trial Piclidenoson for dogs, with Phase 2 results due Q3 2026. Yet, one analyst still rates the stock as a Hold. Read on to see why. More >

First US Brain-Only PET Clinic Targets Alzheimer's Detection as Diagnostic Demand Expands
Source: Streetwise Reports  (3/27/26)
Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is opening its inaugural brain PET clinic in Florida with a five-year lease and renewal option. More >

Massachusetts Biotech Co. Finds High-Potential Muscle Treatment Breakthrough
Source: Streetwise Reports  (3/27/26)
Sarepta Therapeutics Inc.'s (SRPT:NASDAQ) early results reveal dose-dependent drug exposure and significant biomarker reductions for forms of muscular dystrophy. More >

Biotech Company Achieves Key Bladder Cancer Milestone in California
Source: Streetwise Reports  (3/27/26)
ImmunityBio Inc. (IBRX:NASDAQ) confirms study power sufficiency for ANKTIVA combo, supporting measurable response outcomes and maintaining timeline for 2026 BLA filing. More >

Biotech Price Target Raised on Strong FSHD and DM1 siRNA Data
Source: Dr. Yun Zhong  (3/27/26)
Wedbush Securities raised its price target on Sarepta Therapeutics Inc. (SRPT:NASDAQ), following promising Phase 1/2 data for siRNA candidates SRP-1001 in FSHD and SRP-1003 in DM1, citing superior muscle concentration and a clean safety profile versus rival programs from Novartis and Dyne Therapeutics. More >

America's First Brain-Dedicated PET Scanning Clinics: A Turnaround Play for Chart-Savvy Investors?
Source: Stewart Thomson  (3/26/26)
Technical Analyst Stewart Thomson explains why he thinks Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is a Strong Speculative Buy. More >

Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline
Source: Mitchell Kapoor  (3/26/26)
H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics Inc. (SRPT:NASDAQ), arguing that promising but early-stage siRNA muscle concentration data in DM1 and FSHD cannot compensate for falling ELEVIDYS sales, a fatal adverse event in SRP-1003, and intensifying competition from Avidity and Dyne ahead of a potential 2030 market entry. More >

Neuroscience Co. Enters Catalyst-Rich 2026 With Multiple Phase 2 Readouts and US$120M Financing
Source: Patrick Trucchio  (3/25/26)
H.C. Wainwright reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE), citing upcoming Phase 2 data readouts for ALTO-101, ALTO-300, and ALTO-100, plus US$120 million financing to advance ALTO-207 in treatment-resistant depression through Phase 3. More >

Buy Rating Reaffirmed: ALTO-207 TRD Trial on Track
Source: Paul Matteis  (3/25/26)
Stifel reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE) after an in-line Q4 2025 earnings report. More >

Biotech Company Accelerates AI Detection Breakthrough Globally
Source: Streetwise Reports  (3/20/26)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) advanced AI-powered screening kiosks, targeting safer operations across industrial sectors. More >

Durham, NC Biopharma Co. Finds High-Growth Drug Opportunity
Source: Streetwise Reports  (3/20/26)
Pelthos Therapeutics Inc. (PTHS:NYSEAmerican) delivered massive growth from its drug launch, with bullish forecasts signaling upside, according to analysts. More >

Life Sciences Firm Advances Massive US$2.4B Market Opportunity
Source: Streetwise Reports  (3/18/26)
Cleantech and life sciences leader BioLargo Inc. (BLGO:OTCQX) announces that clinical experiences with ViaCLYR were presented at a symposium in Hawaii. More >

An AI-Powered Doctor & Patient Platform: Why This North American Provider is Gaining Market Momentum
Source: Stewart Thomson  (3/17/26)
Technical Analyst Stewart Thomson explains why he likes Rocket Doctor AI Inc. (AIDR:CSE; TREIF:OTC; 939:FRA). More >

Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch
Source: Andrew Fein  (3/16/26)
H.C. Wainwright reiterated its rating and price target on Savara Inc. (SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market. More >

Bothell, WA Bio Co. Poised for 17-20% Revenue Growth in 2026 as Cell Therapy Market Expands
Source: Dr. Yi Chen  (3/13/26)
BioLife Solutions Inc. (BLFS:NASDAQ) reported strong 2025 results. The company is now a pure-play cell processing business, expecting double-digit growth driven by expanding cell and gene therapy adoption, according to an H.C. Wainwright & Co. research note. More >

Analyst Maintains Spec Buy on Biotech After Interim SAT-3247 DMD Data
Source: Dr. Douglas Loe  (3/11/26)
Leede Financial maintained its rating on Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ), with a US$16.00 price target following updated interim Phase II SAT-3247 data from the TRAILHEAD trial in Duchenne muscular dystrophy. More >

A New Infection Control Platform Launched
Source: John Newell  (3/11/26)
John Newell of John Newell & Associates shares his thoughts on BioLargo Inc. (BLGO:OTCQX) to explain why he thinks the stock is a Speculative Buy. More >

Medical Co.'s TULSA-PRO Installed Base Growth and CAPTAIN Trial Data Could Accelerate Adoption in 2026"
Source: Dr. Douglas Loe  (3/9/26)
Leede Financial maintained its rating on Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), citing strong TULSA-PRO capital sales, expanding installed base, and upcoming CAPTAIN trial results at EAU meeting as key catalysts. More >

Cannabis Producer Moves to the TSX as Analyst Flags Major Expansion Potential
Source: Streetwise Reports  (3/9/26)
Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE) began trading on the Toronto Stock Exchange on March 2 after graduating from the TSX Venture Exchange. Atrium Research initiated coverage with a BUY rating and CA$3.00 target, citing best-in-class EBITDA margins of 29%. More >

Target Raised on CA Pharma Co. as EBITDA Margins Sustain Upward Trajectory
Source: Dr. Douglas Loe  (3/6/26)
Leede Financial maintains its current rating on CareRx and raised its target price, following FQ425 results showing continued sequential improvement in EBITDA, margins, and operating cash flow. More >

Record Profits, a Vape Market Landgrab, and a CA$250M Facility Bought for CA$27M
Source: Nicholas Cortellucci  (3/5/26)
Atrium Research initiated coverage on Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE), citing the company's dominant position in Quebec's new vape category, best-in-class EBITDA margins of 29%, and a capital-efficient expansion path at its Valleyfield facility that could unlock 100,000 kg of annual production capacity by FY30. More >

Biotech With Groundbreaking Diabetes Treatment Secures CA$7.1M Breakthrough Financing
Source: Streetwise Reports  (3/5/26)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) successfully secured financing transactions totaling CA$7.1 million, significantly bolstering the company's financial stability. Find out how one analyst rates the stock. More >

Biotech Expands Financing to CA$2M as AI-Driven Cancer Drug Programs Advance
Source: Streetwise Reports  (2/24/26)
Rakovina Therapeutics Inc. (RKV:TSX.V) increased its previously announced financing to approximately US$2.0 million through a convertible debenture and private placement. The company stated the proceeds will support working capital needs and ongoing corporate and strategic initiatives. More >